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Abstract. We recently reported the production of the recombinant kinesin-related protein of Leishmania donovani
with a molecular weight of 42 kd (rKRP42) and the value of the antigen in serum-based ELISA for the diagnosis of
visceral leishmaniasis (VL). In this study, the rKRP42 antigen was validated with ELISA using urine samples (rKRP42
urine ELISA). The urine-based ELISA showed 94% sensitivity (108 positives among 115 VL samples) and 99.6%
specificity (239 negatives among 240 non-VL samples). The sensitivity and specificity are almost similar to our previous
results by ELISA with acetone-treated L. donovani promastigote antigen and direct agglutination test, both methods
being done by use of urine samples. A comparison of the rKRP42 urine ELISA with the commercially available urinary
antigen detection kit (KAtex) using 108 VL samples showed much higher sensitivity of the ELISA (96.3%) than KAtex
(55.6%). The use of the rKRP42 antigen with urine samples will facilitate epidemiologic studies.
INTRODUCTION
Visceral leishmaniasis (VL) is caused by a protozoan para-
site Leishmania donovani complex. In full-blown disease, the
mortality rate ranges from 80% to 100% if not treated. Even
with treatment, sometimes the case fatality rate reaches
> 10%.1 Recently, in a population-based study in Bangladesh,
Ahlwalia and others2 reported a VL incidence of 2% per year
from 2000 to 2002, with a case fatality rate of 19% among
adult women ( 15 years of age) and 6–8% among the other
demographic groups (girls < 15 years of age and males of all
ages). They also reported that the median duration of illness
before receiving treatment was significantly longer in females
than males. Delays in diagnosis and treatment increase the
risk of complications and death.1 VL is targeted for control
under the neglected tropical diseases program.3 The effective
control of VL has been hampered because of the lack of
suitable tools for early detection of infection and effective
chemotherapy. Therefore, an accurate, easy, and low-cost di-
agnostic method is an urgent necessity.
Because of invasiveness and inadequate sensitivities, dem-
onstration of the causative parasites in aspirates from lymph
nodes, bone marrow, and the spleen has limited its use in a
field survey.4 In the last two decades, several serodiagnoses,
like ELISA with crude or recombinant antigens,5–7 and direct
agglutinin test (DAT),8,9 have been providing good diagnostic
results. However, the use in endemic areas has been limited
because of the expertise required for execution. In Bangla-
desh, DAT only has been available for clinicians at the Insti-
tute of Epidemiology, Disease Control and Research
(IEDCR) situated in the capital, Dhaka. Recently, a recom-
binant antigen rK39, a part of L. chagasi kinesin-related pro-
tein, has been widely evaluated with ELISA or in dipstick
format.10,11 Although the antigen has been reported satisfac-
tory in Indian subcontinent, the results varied considerably in
different endemic areas. In India and Nepal,12–14 the test
showed the highest sensitivity of 100%, whereas it was sig-
nificantly lower in Venezuela (88%),15 in southern Europe
(71.4%),16 and in Sudan (67%).17 The variation could be ex-
plained by differences in subspecies of L. donovani com-
plexes, genetic differences in individual patients or in racial
subgroups, and epidemiologic factors such as the length or
severity of diseases.18 Thus, it is desirable to develop new
antigens for comparison. Recently, we reported the produc-
tion of recombinant protein rKRP42, a part of L. donovani
kinesin-related protein and a homolog to rK39, and evalua-
tion of this antigen in ELISA with serum samples for the
diagnosis of VL.19
Recently, the use of urine for blood has been considered
valuable for the diagnosis of VL. A low-molecular-weight
heat-stable leishmanial carbohydrate antigen was detected in
urine by a latex agglutination test (KAtex).20,21 We reported
an ELISA with urine samples using acetone-treated L. dono-
vani promastigotes antigen (acetone-treated urine ELISA),22
and a direct agglutination test with urine samples (urine
DAT)23 for the diagnosis of VL, which showed, respectively,
sensitivities of 95% and 90.7% and specificities of 95.3% and
97.3%. These figures are almost comparable to serum-based
ELISA and DAT. In this study, we report the usefulness of
rKRP42 antigen in a new urine ELISA and compare the re-
sults with other urine-based immunologic tests.
MATERIALS AND METHODS
Urine and serum samples. Most urine samples tested in this
study were the same ones used in our previous study.23 Ad-
ditional samples from 44 VL patients and 17 Japanese healthy
controls were included. A total of 115 urine samples from
defined VL patients, collected from different medical college
hospitals (96 from Rajshahi Medical College hospital, 11 from
Mymensingh Medical College hospital, and 8 from Institute
of Epidemiology, Disease Control and Research) in Bangla-
desh, were used to compute sensitivity of rKRP42 urine
ELISA. VL was diagnosed in accordance with the WHO
guideline of initiation of treatment.24 Briefly, the diagnosis
was based on well-defined clinical symptoms along with sup-
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portive hematologic features (anemia, leucopenia, reversed
albumin globulin ratio, etc.) and was confirmed by parasito-
logic test or at least by one serologic test. The clinical symp-
toms included at least three of the following symptoms: in-
termittent chronic fever for > 1 month, splenomegaly, hepa-
tomegaly, anemia, wasting, and lymphadenopathy. Malaria,
tuberculosis, enteric fever, and other diseases that could pro-
duce similar clinical symptoms had been ruled out as much as
possible. Among the 115 patients, 40 were confirmed parasi-
tologically: Leishman-Donovan bodies were detected in
smears of splenic aspirates (30 patients) or bone marrow as-
pirates (5 patients), and promastigotes were shown in 5 pa-
tients after inoculation of aspirate materials in Novy, Mac-
Neal, and Nicolle medium. Of the other 75 clinically con-
firmed patients, 47, 9, and 19 were positive by conventional
DAT, aldehyde test, and rK39 dipstick test, respectively. At
the time of sample collection, patients were either in the
course of treatment with sodium antimony gluconate at a
WHO-recommended dose25 or just before the initiation of
treatment. A total of 240 non-VL urine samples were used for
a specificity study. Fifty-nine control samples were taken from
apparently healthy individuals with no past history of kala-
azar from endemic areas in Bangladesh (endemic healthy
control [EHC]). Eighty samples from Japanese individuals
were used as non-endemic healthy controls (NEHC). Fifty-
eight malaria samples collected in Solomon Islands, 13 tuber-
culosis samples from Bangladesh, 23 cutaneous leishmaniasis
(CL) samples from Ecuador, and 7 samples from patients with
other diseases were also included. Other diseases category
included amebic liver abscess (2 cases), aplastic anemia (2),
aplastic anemia with nephrotic syndrome (1), aortic stenosis
(1), and viral fever (1). Immediately after collection of urine,
NaN3 was added to each sample at the final concentration of
0.1% as preservative, and the samples were transported to
Japan at ambient temperature and kept at 4°C until immu-
nologic tests.
The study was reviewed and approved by the Ethics Com-
mittee of Aichi Medical University School of Medicine, Ja-
pan, and the Ethical Review Committee of the Bangladesh
Medical Research Council.
Effect of storage of urine samples on L. donovani–specific
IgG titers. This study included urine samples that had been
collected > 6 years before. To study the effect of storage of
NaN3-added urine samples at 4°C, L. donovani–specific IgG
titers of the same urine samples from 51 VL and 211 non-VL
subjects were measured with acetone-treated urine ELISA at
three different times: the first measurement with relatively
fresh urine samples (collected within 1 year) was in February
2001, the second one in May 2003, and the third one in No-
vember 2007. The ELISA with acetone-treated L. donovani
promastigotes antigen was described elsewhere.22 The mea-
surement (all in duplicate) was standardized using a set of
serially diluted positive sera prepared for every microtiter
plate. The sensitivities and specificities obtained in the three
measurements were compared using the 2 test, and the geo-
metric mean IgG titers were compared using paired t test.
The rKRP42 urine ELISA. The production of rKRP42 an-
tigen was described elsewhere.19 An ELISA was performed
as follows. Flat-bottomed 96-well microtiter plates (Maxi-
Sorp; Nunc, Roskilde, Denmark) were coated with 1 g/mL
(100 L/well) rKRP42 antigen and incubated overnight at
4°C. After blocking with casein buffer (1% casein in 0.05
mol/L Tris-HCl buffer with 0.15 mol/L NaCl, pH 7.6) for 2
hours at room temperature, the wells were loaded with 100
L of urine without concentration and incubated at 37°C for
1 hour. After four washes with PBS(−) (pH 7.4) containing
0.05% Tween 20, peroxidase-conjugated goat anti-human
IgG (Tago, Camarillo, CA), diluted 1:4,000 with casein buffer,
was added and incubated at 37°C for 1 hour. After washing
four times, ABTS substrate (KPL, Gaithersburg, MD) was
reacted for coloration for 1 hour at room temperature. The
optical density was measured at 415 and 492 nm as reference.
Each sample was assayed in duplicate, in which, if the absor-
bance values of the duplicates differ > 40% from their aver-
age, the sample was retested. Antibody levels were expressed
arbitrarily as unit (U), which was estimated from the standard
curve constructed for each plate with serially diluted positive
sera. The cut-off point for anti-rKRP42 IgG was first calcu-
lated as the mean plus 3 SDs of log (unit + 1) values of the
NEHC, and [antilog of (the mean + 3 SDs) − 1] was regarded
as the cut-off unit.
Urine latex agglutination test (KAtex). The KAtex was
performed with 108 VL (7 VL samples could not be tested
because of inadequate quantity) and 240 non-VL urine
samples according to the manufacturer’s protocol (Kalon Bio-
logical, Aldershot, UK) except that 100 L of urine was used
for pretreatment of 5-minute boiling instead of recommended
250 L to 1 mL. Before changing the volume of urine, we
tested 10 urine samples and confirmed that the use of 100 L
did not influence the results. After bringing all the test re-
agents to ambient temperature, 50 L of urine sample was
placed to a reaction zone in the glass slide, and a drop of test
latex was added to it. The liquids were stirred to a completely
homogenous mixture and rotated continuously for 2 minutes.
A negative control in the reaction zone next to the test sample
was run each time. Any agglutination discerned compared
with the negative control was considered positive.
RESULTS
Effect of storage of urine samples. Fifty-six VL and 211
non-VL urine samples stored at 4°C were tested with the
acetone-treated urine ELISA in February 2001, May 2003,
and November 2007, which showed sensitivities of 91.1%,
91.1%, and 82.1% and specificities of 95.3%, 97.2%, and
98.1%, in order of measurement (Table 1). There were no
differences among the sensitivities (2 test, 2 df, P > 0.24) and
the specificities (2 test, 2 df, P > 0.23). The mean IgG units
in the first, second, and third measurements with the VL
samples were 103.10, 83.86, and 61.11 U, respectively, and
those with the non-VL samples were 0.93, 0.94, and 0.89 U,
respectively (Table 1). In the VL samples, paired t test
showed significant differences between the first and second
means (P < 0.012), the second and third means (P < 0.002),
and the first and third means (P < 0.001). Because the first
measurement was done with relatively fresh samples, we con-
sidered its mean unit as 100% and calculated the percentages
of IgG units in the second and third measurements. They
were 81.3% and 59.3%, respectively (Table 1). The percent-
age reduction, when plotted on a graph, showed an approxi-
mate linearity, and a yearly rate of reduction was estimated to
be 6.0% (40.7% reduction in 6.8 years). In the non-VL
samples, no significant differences were obtained (P > 0.28 in
all comparisons).
ISLAM AND OTHERS600
The rKRP42 Urine ELISA. A total of 115 VL and 240
non-VL samples were tested for IgG using rKRP42 antigen
(Figure 1). With the NEHC group, the cut-off was determined
as 57.9 U, based on which the test showed a sensitivity of
94.0% (108 positives among 115 VL samples) and a specificity
of 99.6% (239 negatives among 240 non-VL samples). Of the
108 positive VL samples, only 10 had titers < 1,000 U. There
was no difference between the sensitivities when calculated
with the parasite-confirmed VL group (92.5% with 40
samples) and clinical VL group (94.7% with 75 samples; 2
test, P > 0.64). The specificities for EHC, NEHC, M, TB, and
CL were 100%. Only one sample of other diseases category
(aplastic anemia with nephrotic syndrome) became positive
by the test.
KAtex. The urinary antigen detection assay KAtex showed
a low sensitivity of 55.6% (60 positives among 108 VL
samples) and a high specificity of 100% with 240 non-VL
samples. Among the 108 VL samples, 36 were parasite posi-
tive, the rest (72) were clinical VL, and the KAtex positive
rate for the former group was 63.9% (23 positives) and for the
latter group was 51.4% (37 positives). No significance differ-
ence was obtained between the groups (2 test, P > 0.21). In
this study, 13 samples (of which 5 were parasitologically con-
firmed) were collected before initiation of treatment, and the
rest (95 samples) were collected at various times in the course
of treatment. Further analysis showed that the pre-treatment
samples had a high sensitivity of 76.9%, whereas the treated
samples had much lower sensitivity (44–54%; Table 2). How-
ever, the difference between the pre- and undertreatment (all
combined) samples was not significant (2 test, P > 0.09).
DISCUSSION
Because most of the urine samples used in this study were
stored at 4°C for years, it would be essential to study the
effect of storage on sensitivity, specificity, and the level
of antibody unit, and for the study, acetone-treated urine
TABLE 1
Effect of storage of samples on sensitivity and specificity and on mean antibody unit with acetone treated urine ELISA
Measurement time
2001 February 2003 May 2007 November
Sensitivity 91.1% (51/56) 91.1% (51/56) 82.1% (46/56)
Specificity 95.3% (201/211) 97.2% (205/211) 98.1% (207/211)
Mean antibody unit (%) VL 103.10 (100.0) 83.86 (81.3) 61.11 (59.3)
Non-VL 0.93 (100.0) 0.94 (101.2) 0.89 (95.5)
FIGURE 1. Detection of anti-rKRP42 IgG in urine of visceral leishmaniasis patients, healthy individuals, and controls with various diseases by
ELISA. Each symbol (●) stands for a single urine sample. The horizontal dotted line represents the cut-off value: 57.9 U. VL  visceral
leishmaniasis; EHC  endemic healthy controls; NEHC  non-endemic healthy controls; M  malaria; TB  tuberculosis; CL  cutaneous
leishmaniasis; OD  other diseases; n  number of samples.
rKRP42 URINE ELISA TO DIAGNOSE VISCERAL LEISHMANIASIS 601
ELISA was applied. The storage clearly decreased mean an-
tibody units at a rate of 6% annually in the VL group. To the
best of our knowledge, this is the first quantitative report on
the reduction of L. donovani–specific antibody after long-
term storage of NaN3-added urine samples at 4°C. Thus, the-
oretically, urine storage could decrease sensitivity and at the
same time might improve specificity. However, such effects
will be only on borderline positive titers. In this study, up to
6 years and 8 months of storage did not affect the sensitivity
and specificity at a statistically significant level.
The rKRP42 urine ELISA with samples kept for years
showed a high sensitivity of 94%. The ELISA also resulted in
a very high specificity of 99.6%. These results are comparable
to our previously reported figures obtained by the acetone-
treated urine ELISA, urine DAT, and rKRP42 serum
ELISA. The commercially available rK39 dipstick test (In-
Bios International, Seattle, WA) also gave similar results in
our study in Bangladesh (Table 3).
When three different methods for urinary antibody detec-
tion (rKRP42 urine ELISA, acetone-treated urine ELISA,
and urine DAT) were taken into consideration, a total 90.1%
(64 of 71) VL samples were positive and 95.9% (211 of 220)
of non-VL samples were negative by all three tests. Variable
results, i.e., positive by one test but negative by other test(s),
were obtained in 3 of 71 VL samples (4.2%), and 8 of 220
non-VL samples (3.6%). All these methods failed to detect
four VL cases, of which three were parasite positives, or
cross-reacted with one non-VL sample that was collected
from a patient of aplastic anemia with nephrotic syndrome.
When we compared the rKRP42 urine ELISA with the
rKRP42 serum ELISA and the rK39 dipstick test using 71 VL
cases, 65 (91.5%) samples became positive and 4 (4.6%)
samples were negative in all assays. Two samples from one
parasite-confirmed and one clinical VL gave false-negative
results with rKRP42 urine ELISA but were positives by
rKRP42 serum ELISA. Of the four false negatives, three
were collected from parasitologically confirmed patients.
These three samples gave false-negative results with conven-
tional serum-based DAT23 and with urinary antibody detec-
tion assays (acetone-treated urine ELISA and urine DAT).
There is always a fraction of infected persons without clini-
cal manifestations. Khalil and others26 reported that, in east-
ern Sudan, the ratios of clinical and subclinical cases in Um-
Salala village, respectively, in 1994/95 and 1995/96, were 1.2:1
and 2.6:1, and in Mashrau Koka village were 1:11 and 1:2.5. In
another study conducted in Bihar state, India, 69% of asymp-
tomatic seropositves by rK39 ELISA and dipstick developed
kala-azar within 1 year,27 suggesting that many of the asymp-
tomatic cases were in a pre-clinical state. In predicting pos-
sible clinical cases, an ELISA, which is quantitative, would be
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TABLE 2
KAtex-positive rate in relation to sample collection day with treat-
ment
Sample collected on the day after
initiation of treatment
Tested
samples KAtex positives
0 (before initiation of treatment) 13 76.9% (10/13)
1∼10 9 44.4% (4/9)
11∼20 15 53.3% (8/15)
21∼30 or more 6 50.0% (3/6)
No clear history* 65 53.8% (35/65)
* In the patient’s data sheets, the exact date of collection was not mentioned, but all the
samples were collected within the course of treatment
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more advantageous than a dipstick format, that is, high anti-
body titers, or increase in antibody titers with time could be
indicative of possible clinical cases. Such early diagnosis will
have a practical importance now that oral treatment with
miltefosine has become available.28 However, frequent col-
lection of blood often hinders the field surveys. Urine samples
that can be easily and safely collected will solve many of the
difficulties experienced with blood collection in a field study,
especially with children.
Antigen detection is more useful than antibody detection
for diagnosing active VL cases. KAtex has been widely evalu-
ated in many places such as in Nepal29 and India30 and found
to have a sensitivity of 47.7% and 73.5%, respectively. In this
study, the sensitivity and specificity of KAtex was 55.6% and
100%, respectively. Because the study included urine samples
from clinically suspected cases and undertreatment cases, the
sensitivity could be an underestimate. In our separate study, it
was observed that six of seven KAtex-positive cases turned
negative after completion of 28-day course of sodium stibo-
gluconate treatment, suggesting its diagnostic and prognostic
value.
The rKRP42 urine ELISA has been shown to be highly
sensitive and specific. The stability of urinary antibody at 4°C
even after prolonged storage has also been confirmed. Our
rKRP42 urine ELISA would be a better alternative for the
diagnosis of VL in a field survey, especially when repeated
sampling is needed. KAtex that uses urine would be good
adjunct for determining the active VL cases among rKRP42
urine ELISA positives.
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